GSK is a global biopharmaceutical company with a purpose to unite science, technology, and talent to get ahead of disease together. With a rich history spanning over 300 years through its legacy companies, GSK focuses on delivering innovative vaccines and specialty medicines to prevent and treat a wide range of diseases. The company prioritizes R&D in areas like infectious diseases, HIV, oncology, and immunology, leveraging the science of the immune system, human genetics, and advanced technologies to make a positive impact on global health.
The new global headquarters serves as the central hub for GSK's strategic leadership, corporate functions, and is designed to foster collaboration and innovation across the company.
A state-of-the-art, sustainable building (BREEAM Excellent rated) designed to promote agile working, collaboration, and employee wellbeing. It is located in a vibrant, well-connected area near Tottenham Court Road.
Aims to foster a modern, inclusive, and dynamic work environment, encouraging innovation, teamwork, and reflecting GSK's 'Ahead Together' culture. The space is designed for flexibility and to support diverse working styles.
This strategic relocation places GSK in a leading global innovation hub, enhancing its ability to attract top talent and collaborate with partners. It signifies a commitment to a modern, progressive, and sustainable operational footprint.
GSK operates in over 100 countries worldwide, with a significant presence in North America, Europe, Asia Pacific, Latin America, and Africa. Its global functions include research and development at major R&D hubs, a network of manufacturing sites producing medicines and vaccines, and extensive commercial operations to ensure its products reach patients who need them. GSK is also committed to global health, working to improve access to its products in developing countries.
The Earnshaw, 20-28 Denmark Street
London
England
United Kingdom
Address: GSK US Headquarters, Navy Yard, 5 Crescent Drive, Philadelphia, PA 19112, USA
Manages and supports GSK's extensive portfolio of medicines and vaccines within the US, engages with regulatory bodies like the FDA, and drives market access, research, and commercialization efforts in North America.
Address: Avenue Fleming 20, 1300 Wavre, Belgium (GSK Vaccines Global HQ)
Coordinates global vaccine strategy, R&D pipelines, manufacturing networks, and distribution for GSK's diverse portfolio of vaccines aimed at preventing diseases across all stages of life, worldwide.
Address: GSK Asia House, 23 Rochester Park, Singapore 139234
Coordinates GSK's business development, supply chain, and market strategies for countries within the APAC region, adapting to local healthcare needs, regulatory environments, and fostering partnerships.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, GSK' leadership includes:
GSK has been backed by several prominent investors over the years, including:
GSK has experienced key leadership transitions in the past 12-18 months, most notably with the appointment of a new Chief Financial Officer in 2023. These changes align with the company's strategic priorities and ongoing evolution as a focused biopharma entity.
Discover the tools GSK uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
GSK primarily utilizes the [first].[last]@gsk.com email format for its employees. While variations might exist for specific roles or regions, this is the most common and recognized pattern for professional communication with GSK personnel.
[first].[last]@gsk.com
Format
jane.doe@gsk.com
Example
90%
Success rate
GSK Press Release • June 7, 2024
The US Food and Drug Administration (FDA) has approved an expanded indication for Arexvy (Respiratory Syncytial Virus Vaccine, Adjuvanted), making it the first RSV vaccine available for adults aged 50-59 who are at increased risk for severe outcomes from the respiratory virus....more
GSK Press Release • May 1, 2024
GSK announced strong financial results for the first quarter of 2024, with sales up 10% to £7.4 billion and adjusted EPS up 28%. Growth was driven by strong performances in Vaccines (Arexvy, Shingrix) and Specialty Medicines (HIV portfolio). The company raised its full-year 2024 guidance....more
GSK Press Release • April 25, 2024
GSK plc announced it has completed the acquisition of Aiolos Bio, Inc., a clinical-stage biopharmaceutical company focused on treatment of respiratory and inflammatory conditions. The acquisition includes AIO-001, a potentially best-in-class, long-acting anti-TSLP monoclonal antibody ready to enter phase II development for asthma....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including GSK, are just a search away.